Analyst Expectations For 10x Genomics’s Future – 10x Genomics (NASDAQ:TXG)

10x Genomics TXG has been analyzed by 12 analysts within the final three months, revealing a various vary of views from bullish to bearish.

The desk under affords a condensed view of their latest rankings, showcasing the altering sentiments over the previous 30 days and evaluating them to the previous months.

Offering deeper insights, analysts have established 12-month worth targets, indicating a mean goal of $15.5, together with a excessive estimate of $26.00 and a low estimate of $9.00. A detrimental shift in sentiment is obvious as analysts have decreased the common worth goal by 20.51%.

Exploring Analyst Rankings: An In-Depth Overview

The evaluation of latest analyst actions sheds gentle on the notion of 10x Genomics by monetary consultants. The next abstract presents key analysts, their latest evaluations, and changes to rankings and worth targets.

Key Insights:

Motion Taken: Analysts adapt their suggestions to altering market circumstances and firm efficiency. Whether or not they ‘Keep’, ‘Elevate’ or ‘Decrease’ their stance, it displays their response to latest developments associated to 10x Genomics. This info gives a snapshot of how analysts understand the present state of the corporate.
Score: Offering a complete evaluation, analysts supply qualitative assessments, starting from ‘Outperform’ to ‘Underperform’. These rankings mirror expectations for the relative efficiency of 10x Genomics in comparison with the broader market.
Worth Targets: Analysts predict actions in worth targets, providing estimates for 10x Genomics’s future worth. Inspecting the present and prior targets affords insights into analysts’ evolving expectations.

For useful insights into 10x Genomics’s market efficiency, take into account these analyst evaluations alongside essential monetary indicators. Keep well-informed and make prudent choices utilizing our Rankings Desk.

Keep updated on 10x Genomics analyst rankings.

If you’re taken with following small-cap inventory information and efficiency you can begin by monitoring it right here.

Delving into 10x Genomics’s Background

10x Genomics Inc is a life science know-how firm based mostly in america. Its options embody devices, consumables, and software program for analyzing organic programs. The corporate’s built-in options embody devices, consumables, and software program for analyzing organic programs at a decision and scale that matches the complexity of biology. Its product choices embody a Chromium platform comprising microfluidic chips and associated consumables, Chromium X collection, Visium and Xenium platforms, and others, that are predominantly used for the examine of organic elements. Geographically, the corporate derives most income from america and the remainder from Americas (excluding america), Europe, Center East and Africa, China, and Asia-Pacific (excluding China).

10x Genomics’s Financial Affect: An Evaluation

Market Capitalization: With restricted market capitalization, the corporate is positioned under business averages. This displays a smaller scale relative to friends.

Income Progress: 10x Genomics’s income progress over a interval of 3M has confronted challenges. As of 31 March, 2025, the corporate skilled a income decline of roughly -6.14%. This means a lower within the firm’s top-line earnings. As in comparison with opponents, the corporate encountered difficulties, with a progress fee decrease than the common amongst friends within the Well being Care sector.

Internet Margin: The corporate’s web margin is under business benchmarks, signaling potential difficulties in reaching sturdy profitability. With a web margin of -22.18%, the corporate might have to deal with challenges in efficient value management.

Return on Fairness (ROE): 10x Genomics’s ROE is under business requirements, pointing in the direction of difficulties in effectively using fairness capital. With an ROE of -4.85%, the corporate could encounter challenges in delivering passable returns for shareholders.

Return on Belongings (ROA): 10x Genomics’s ROA is under business requirements, pointing in the direction of difficulties in effectively using belongings. With an ROA of -3.77%, the corporate could encounter challenges in delivering passable returns from its belongings.

Debt Administration: 10x Genomics’s debt-to-equity ratio is under the business common. With a ratio of 0.11, the corporate depends much less on debt financing, sustaining a more healthy stability between debt and fairness, which might be considered positively by traders.

The Core of Analyst Rankings: What Each Investor Ought to Know

Analyst rankings function important indicators of inventory efficiency, supplied by consultants in banking and monetary programs. These specialists diligently analyze firm monetary statements, take part in convention calls, and interact with insiders to generate quarterly rankings for particular person shares.

Some analysts publish their predictions for metrics equivalent to progress estimates, earnings, and income to supply further steering with their rankings. When utilizing analyst rankings, it is very important remember the fact that inventory and sector analysts are additionally human and are solely providing their opinions to traders.

If you wish to hold monitor of which analysts are outperforming others, you may view up to date analyst rankings alongside withanalyst success scores in Benzinga Professional.

Which Shares Are Analysts Recommending Now?

Benzinga Edge offers you prompt entry to all main analyst upgrades, downgrades, and worth targets. Kind by accuracy, upside potential, and extra. Click on right here to remain forward of the market.

This text was generated by Benzinga’s automated content material engine and reviewed by an editor.